Chemogenetic hydrogen sulfide production reverses vascular remodeling in aged mice
Targeting hydrogen sulfide generation to endothelial mitochondria mitigated senescence programs and reversed vascular remodeling in aged mice.
bioRxiv · Shabanian K et al. · Paper published 30 Sep 2026
In aged mice, researchers tested a targeted chemogenetic system to rescue vascular senescence, according to a new preprint. The study notes that hydrogen sulfide bioavailability declines during aging and atherosclerosis, which is associated with endothelial senescence. To address this decline, the authors engineered a remote-control, endothelial-specific, mitochondria-targeted chemogenetic tool. This platform enabled precise spatiotemporal control over hydrogen sulfide generation. Using this targeted approach, the team mitigated endothelial senescence-driven programs. The controlled release of hydrogen sulfide also successfully reversed vascular remodeling in the animals, presenting a targeted strategy to address vascular decline.
Why it matters
Vascular senescence is considered a central driver of whole-body aging. Demonstrating that targeted hydrogen sulfide generation can reverse vascular remodeling provides insight into interventions that might counter age-related vascular dysfunction.
Caveats
The findings are based entirely on aged mice and may not directly translate to humans. Furthermore, this work is a preprint that has not yet completed peer review.
Written from the paper’s abstract, and every claim checked against it before publishing. Read the paper for the full methods and data.
The paper
Chemogenetic Hydrogen Sulfide Rescues Vascular Senescence in Ageing
Shabanian K, Shabanian T, Da Dalt L et al.
bioRxiv · 30 Sep 2026 · Preprint, not yet peer-reviewed
- Relevance
- Core geroscience
- News value
- Important
- Evidence
- Animals
- Status
- Preprint
More on Cellular senescence
See allDasatinib and quercetin reduce liver fibrosis in a phase-2 MASH trial
The senolytic combination improved liver fibrosis without disease worsening in nearly half of treated participants while lowering cellular senescence markers.
Nature metabolism · Koning M et al.
A distinct p21-driven macrophage senotype accumulates during aging and liver disease
Researchers identified a p53-p21-Cyclin D2 axis that governs senescent macrophages in mice and human liver cirrhosis and can be cleared with senolytics.
bioRxiv · Torres G et al.
DNA methylation proxies of senescence markers track human disease and mortality
The new blood-based tools estimate senescence gene activity to predict incident diseases, all-cause mortality, and clinical treatment responses.
medRxiv · Simpson DJ et al.
Bispecific T cell engager eliminates senescent cells in mice and nonhuman primates
Monitored by serum transaminase levels, low doses of the drug alleviated age-related pathologies without causing the hepatotoxicity seen at higher doses.
Aging cell · Deng J et al.
A deep learning score for cellular senescence predicts human mortality and disease risk
The proteomic biomarker tracked chronic illness risk in the UK Biobank and shifted following an 18-month multimodal exercise intervention.
Aging cell · Zhao S et al.